We investigated the cytotoxicity mechanisms of alloantigen-specific human CD4+ and CD8+ cytotoxic T lymphocytes (CTLs) using cells from family members with the Fas gene mutation. Alloantigen-specific CD4+ and CD8+ CTL bulk lines and clones were generated from 2 individuals by stimulation of their peripheral blood lymphocytes with allogeneic Fas−/− or Fas+/− cell lines that were established from B-lymphocytes of a patient with Fas deficiency and her mother, respectively. Both CD4+ and CD8+CTL bulk lines and clones directed against allogeneic HLA antigens exerted cytotoxicity against Fas−/− and Fas+/− cells to almost the same degree. The cytotoxicity of CD4+ and CD8+ CTLs appeared to be Ca2+-dependent and was completely inhibited by concanamycin A, an inhibitor of perforin-mediated cytotoxicity. Messenger RNAs for the major mediators of CTL cytotoxicity, Fas ligand, perforin, and granzyme B were all detected in these CD4+CTLs with the use of the reverse transcriptase polymerase chain reaction. The majority of CD4+ CTL clones that showed Fas-independent cytotoxicity were TH0, as determined by their cytokine production profile. These data, obtained with the use of a novel experimental system, clearly show that the main pathway of cytotoxicity mediated by alloantigen-specific human CD4+as well as by CD8+ CTLs is granule exocytosis, and not the Fas/Fas ligand system.

There is no doubt that cytotoxic T lymphocytes (CTLs) directed against alloantigens play crucial roles in the development of graft rejection and graft-versus-host disease (GVHD) following organ transplantation. Therefore, understanding the cytotoxicity mechanisms of alloantigen-specific CTLs is essential in order to develop effective means of preventing rejection and GVHD.

Two main pathways in CTL-mediated cytotoxicity, ie, granule exocytosis mediated by perforin/granzymes and the Fas/Fas ligand system, have been identified.1,2 The molecular mechanisms of CTL-mediated cytotoxicity have been studied extensively in murine systems with the use of various kinds of mutant and knockout mice, including Fas-mutant lpr,3 Fas ligand-mutant gld,4perforin-deficient,5-8 and granzyme-deficient9mice. These investigations have shown that CD8+ murine CTLs exert cytotoxicity mainly via granule exocytosis, whereas the main pathway of CD4+ murine CTL-mediated cytotoxicity is the Fas/Fas ligand system.10 11 In contrast to these recent advances in our understanding of the mechanisms of murine CTL-mediated cytotoxicity, the details of human CTL-mediated cytotoxicity are still obscure owing to the lack of a suitable experimental system.

Recently, the presence of a disorder due to mutation of the Fasgene, the human counterpart of the lpr mouse, has been discovered.12-14 Since the function of Fas is completely abrogated in these patients, this disease is expected to provide useful materials for investigating the functions of Fas in humans. In the present study, we examined the cytotoxicity mechanisms of alloantigen-specific human CD4+ and CD8+ CTLs using cells from family members with the Fas gene mutation. The results showed that in contrast to murine CD4+ CTLs, the major pathway of alloantigen-specific human CD4+ CTLs appeared to be granule exocytosis, and not the Fas/Fas ligand system, the same as that of CD8+ CTLs.

Fas-deficient family members

Detailed information about the family members with the Fasgene mutation investigated in the present study has been reported previously.15 A homozygous point mutation was present in the splicing acceptor site of intron 3 of the Fas gene of this patient (Fas−/−). This mutation results in the skipping of exon 4 and complete loss of surface Fas expression. The patient's parents were both heterozygous for the same Fasgene mutation (Fas+/−). The HLA types of each donor were as follows: Fas−/−patient, A24/24, B48/48, Cw8/-, DRB1*0401/*0401; Fas+/− mother, A24/2, B48/35, Cw3/-, DRB1*0401/*08032; Fas+/+ unrelated donor M.Y., A26/31, B61/62, Cw3/-, DRB1*0901/*1406; Fas+/+ unrelated donor H.O., A24/24, B52/54, Cw1/-, DRB1*04051/*1502.

Generation of alloantigen-specific CD4+ and CD8+ CTL bulk lines and clones

To generate alloantigen-specific CTL bulk lines and clones, peripheral blood mononuclear cells (PBMCs) from 2 unrelated individuals were cocultured with a mitomycin C (MMC)–treated Epstein-Barr virus–transformed B-lymphoblastoid cell line (B-LCL) established from the patient's PBMCs, or from the mother's PBMCs, in RPMI 1640 medium (Gibco, Grand Island, NY) supplemented with 10% heat-inactivated human AB-type serum, as described previously.16 CD4+ and CD8+ T lymphocytes were isolated from PBMCs that had been stimulated with an allogeneic LCL for 6 days by means of magnetizable polystyrene beads coated with anti-CD4 and anti-CD8 monoclonal antibody (mAb) (DYNAL, Oslo, Norway), respectively. Uncloned CD4+ and CD8+ T lymphocytes were further cultured in RPMI 1640 medium supplemented with 10% human serum and interleukin (IL)–2, stimulated with the allogeneic LCL weekly 3 times, and then used as CTL bulk lines. Alloantigen-specific CD4+ and CD8+CTL clones were established from PBMCs that had been stimulated with an allogeneic LCL by limiting dilution and had been continuously cultured in RPMI 1640 medium supplemented with 10% human serum and IL-2 with repeated stimulation by the allogeneic LCL, as described previously.17 

Cytotoxic assays

Cytotoxicity was examined by standard 5-hour 51Cr release assays using B-LCLs, which are sensitive to Fas-mediated cytotoxicity,18,19 and freshly isolated sheep erythrocyte rosette-nonforming (E) cells, ie, B lymphocytes and monocytes, as target cells, as described previously.20 In order to examine the Ca2+-dependency of CTL-mediated cytotoxicity, ethylene glycol-bis(β-aminoethyl ether)-N, N, N′, N′-tetraacetic acid (EGTA) (Sigma, St Louis, MO) was added to the assay wells at 2 mmol/L with 2 mmol/L MgCl2. In some experiments, concanamycin A (CMA) (Wako, Osaka, Japan) was added to assay wells at 10 nmol/L to inhibit perforin-mediated cytotoxicity.21 Treatment of the cells with EGTA and CMA showed no toxic effect, as determined by the trypan blue exclusion test and 51Cr release assay.

Detection of cytolytic mediator messenger RNA expression

Expression of the main mediators of cytolysis, including perforin, granzyme B, and Fas ligand, by T lymphocytes was examined by reverse transcriptase polymerase chain reaction (RT-PCR), as described previously.22 Total RNA was extracted from CTLs that had been stimulated with allogeneic LCLs 5 days earlier, and complementary DNA (cDNA) was synthesized with Moloney murine leukemia virus reverse transcriptase. Amplification of the cDNAs by PCR was performed for 35 cycles with the use of the following primers: perforin, 5′-ACCAGCAATGTGCATGTGTCTGTG-3′ and 5′-GAAGGAGGCCGTCATCTTGTGCTT-3′; granzyme B, 5′-TGCAGGAAGATCGAAAGTGCG-3′ and 5′-GAGGCATGCCATTGTTTCGTC-3′; Fas ligand, 5′-ATAGGATCCATGTTTCTGCTCTTCCACCTACAGAAGGA-3′ and 5′-ATAGAATTCTGACCAAGAGA- GAGCTCAGATACGTTGAC-3′. The expected lengths of the amplified cDNAs for the cytolytic mediators were 459 base pairs (bp), 180 bp, and 506 bp for perforin, granzyme B, and Fas ligand, respectively.

Cytokine production

For the assays of cytokine production, 1 × 106clone cells and 3 × 105 MMC-treated allogeneic LCLs were suspended in 2 mL RPMI 1640 medium supplemented with 10% fetal calf serum and cultured in 16-mm wells. After 72 hours, the supernatants were collected from each well and were assayed for the production of various cytokines by enzyme-linked immunosorbent assay (ELISA) (Endogen, Woburn, MA).

Cytotoxic activities of alloantigen-specific CD4+ and CD8+ CTL bulk lines and clones

We established 3 CD4+ CTL bulk lines, 4 CD4+CTL clones, 3 CD8+ CTL bulk lines, and 5 CD8+CTL clones from PBMCs of an unrelated individual, M.Y., which had been stimulated with the Fas+/− LCL, and 3 CD4+ CTL bulk lines, 5 CD4+ CTL clones, 3 CD8+ CTL bulk lines, and 6 CD8+ CTL clones from M.Y.'s PBMCs, which had been stimulated with the Fas−/− LCL. Similarly, 3 CD4+ CTL bulk lines, 5 CD4+ CTL clones, 3 CD8+ CTL bulk lines, and 4 CD8+ CTL clones were generated from PBMCs of an unrelated individual, H.O., which had been stimulated with the Fas+/− LCL, and 3 CD4+ CTL bulk lines, 5 CD4+ CTL clones, 3 CD8+ CTL bulk lines, and 4 CD8+ CTL clones were generated from H.O.'s PBMCs, which had been stimulated with the Fas−/− LCL. We used B-LCLs and E cells (B lymphocytes and monocytes) as the target cells, since they express both HLA class I and HLA class II molecules, which are targets of alloantigen-specific CD8+ CTLs and CD4+ CTLs, respectively. The same cytotoxicity patterns were detected in all bulk lines and clones within each group, and representative data for CTL bulk lines and clones from each group are presented in Table 1. Both CD4+ and CD8+ CTLs showed cytotoxicity against allogeneic LCLs, which were used as stimulators, but not against autologous LCL. Since the cytotoxic activity of CD4+ CTL bulk lines and clones, and of CD8+ CTL bulk lines and clones, were inhibited by anti–HLA class II and anti–HLA class I framework mAb, respectively (data not shown), the cytotoxicity mediated by these CTLs seemed to be directed against allogeneic HLA antigens. The degrees of cytotoxicity mediated by CD4+ CTLs against Fas+/− and Fas−/− target cells were almost the same. Similarly, CD8+ CTLs showed almost the same levels of cytotoxicity against Fas+/−and Fas−/− target cells. These data strongly suggest that the cytotoxicity mediated by human CD4+ CTLs, as well as by CD8+ CTLs, is Fas-independent.

Table 1.

Cytotoxicity of alloantigen-specific CD4+and CD8+ CTLs against allogeneic Fas+/−and Fas−/− cells and autologous cells

Donor StimulatorPhenotype Effector % Specific Lysis of Target Cells*
Allo (Fas+/−) LCLAllo (Fas−/−) LCL Allo (Fas+/−) E− Allo (Fas−/−) E− Auto LCL
M.Y. Fas+/− CD4  Bulk #1-1  49.2  45.1 28.0  26.9  8.3  
   Clone #1-1  68.3  64.9 43.7  48.1  2.7  
   Clone #1-2  58.2  54.8 32.9  34.1  3.8  
  CD8  Clone #2-1  66.3 62.0  43.7  41.0  2.9  
 Fas−/− CD4  Bulk #3-1  34.9  31.8  21.8  25.3  9.5 
   Clone #3-1  69.5  63.0  43.7  44.4  3.5 
   Clone #3-2  53.2  57.6  34.5  32.0  3.4 
  CD8  Clone #4-1  68.7  69.6  45.2  40.1 3.9  
H.O.  Fas+/− CD4  Bulk #5-1 45.1  40.3  23.7  27.0  10.9  
   Clone #5-1 56.6  53.0  32.1  35.5  4.4  
   Clone #5-2 67.3  60.4  45.0  41.2  5.0  
  CD8  Clone #6-1  54.9  51.9  39.9  34.1  3.5 
 Fas−/− CD4  Bulk #7-1  56.2  52.9 29.6  31.2  11.4  
   Clone #7-1  70.2  73.9 49.5  50.0  4.7  
   Clone #7-2  62.7  68.9 34.1  38.0  6.3  
  CD8  Clone #8-1  54.1 50.3  34.7  35.7  3.0 
Donor StimulatorPhenotype Effector % Specific Lysis of Target Cells*
Allo (Fas+/−) LCLAllo (Fas−/−) LCL Allo (Fas+/−) E− Allo (Fas−/−) E− Auto LCL
M.Y. Fas+/− CD4  Bulk #1-1  49.2  45.1 28.0  26.9  8.3  
   Clone #1-1  68.3  64.9 43.7  48.1  2.7  
   Clone #1-2  58.2  54.8 32.9  34.1  3.8  
  CD8  Clone #2-1  66.3 62.0  43.7  41.0  2.9  
 Fas−/− CD4  Bulk #3-1  34.9  31.8  21.8  25.3  9.5 
   Clone #3-1  69.5  63.0  43.7  44.4  3.5 
   Clone #3-2  53.2  57.6  34.5  32.0  3.4 
  CD8  Clone #4-1  68.7  69.6  45.2  40.1 3.9  
H.O.  Fas+/− CD4  Bulk #5-1 45.1  40.3  23.7  27.0  10.9  
   Clone #5-1 56.6  53.0  32.1  35.5  4.4  
   Clone #5-2 67.3  60.4  45.0  41.2  5.0  
  CD8  Clone #6-1  54.9  51.9  39.9  34.1  3.5 
 Fas−/− CD4  Bulk #7-1  56.2  52.9 29.6  31.2  11.4  
   Clone #7-1  70.2  73.9 49.5  50.0  4.7  
   Clone #7-2  62.7  68.9 34.1  38.0  6.3  
  CD8  Clone #8-1  54.1 50.3  34.7  35.7  3.0 
*

Cytotoxicity of CD4+ and CD8+ CTL bulk lines and clones generated by stimulation of PBMCs isolated from unrelated donors with HLA class I and class II-mismatched Fas+/− or Fas−/− LCL against Fas+/− and Fas−/− target cells, as detailed in “Materials and methods.” Effector/target ratios were 5:1.

Expression of cytolytic mediators in alloantigen-specific CTL clones

RT-PCR revealed that the main cytolytic mediators of CTLs, including perforin, granzyme B, and Fas ligand, were all expressed in all of the CD4+ and CD8+ CTL bulk lines and clones examined. Representative RT-PCR data are shown in Figure1. Expression of both perforin and Fas ligand was confirmed by flow cytometry using anti-perforin and anti-Fas ligand mAbs (data not shown).

Fig. 1.

Expression of cytolytic mediators in alloantigen-specific human CD4+ and CD8+ CTLs. Expression of messenger RNAs (mRNAs) for perforin, granzyme B, and Fas ligand was investigated by RT-PCR. The mRNAs were extracted from CD4+clone #1-1 (lane 1), CD4+ clone #3-1 (lane 2), CD8+ clone #2-1 (lane 3), CD8+ clone #4-1 (lane 4), and a negative control B-cell line (lane 5). Lane M shows 100-bp ladder markers.

Fig. 1.

Expression of cytolytic mediators in alloantigen-specific human CD4+ and CD8+ CTLs. Expression of messenger RNAs (mRNAs) for perforin, granzyme B, and Fas ligand was investigated by RT-PCR. The mRNAs were extracted from CD4+clone #1-1 (lane 1), CD4+ clone #3-1 (lane 2), CD8+ clone #2-1 (lane 3), CD8+ clone #4-1 (lane 4), and a negative control B-cell line (lane 5). Lane M shows 100-bp ladder markers.

Close modal

Inhibition of cytotoxicity mediated by CD4+and CD8+ alloantigen-specific CTL clones by EGTA and CMA

It is well known that perforin-mediated cytotoxicity is Ca2+-dependent. As shown in Table2, the cytotoxicity mediated by both CD4+ and CD8+ CTLs was inhibited completely by addition of the Ca2+-chelating agent EGTA, indicating that their cytotoxicity is Ca2+-dependent. In addition, the cytotoxicity mediated by both CD4+ and CD8+CTLs appeared to be abrogated by the inhibitor of perforin-mediated cytotoxicity, CMA. These data show that the main pathways of cytotoxicity mediated by alloantigen-specific human CD4+and CD8+ CTLs are both granule exocytosis.

Table 2.

Inhibition of cytotoxicity mediated by alloantigen-specific CD4+ and CD8+ CTLs by EGTA and CMA

Donor StimulatorPhenotype Effector % Specific Lysis of Target Cells*
Allo LCL (Fas+/−) Allo LCL (Fas−/−)
None EGTACMA None EGTA CMA
M.Y.  Fas+/− CD4  Bulk #1-1  45.8  0.8  1.5  43.0  0  
   Clone #1-1  76.1  2.6  0.5  75.0  0.1 0.9  
   Clone #1-2  52.8  0.3  0.1  49.8 0.1  0  
  CD8  Clone #2-1  78.0  2.0  0.4 76.9  2.0  1.7  
 Fas−/− CD4 Bulk #3-1  34.0  0  0.3  38.9  0.7  1.0 
   Clone #3-1  69.2  0.1  0.5  65.8  0.8  
   Clone #3-2  60.0  1.0  0  58.2 0  0  
  CD8  Clone #4-1  78.9  2.1  1.0 76.3  0.8  0.3  
H.O.  Fas+/− CD4 Bulk #5-1  42.9  0.5  1.6  40.5  0.6  
   Clone #5-1  65.2  0.6  1.0  66.6  1.7  
   Clone #5-2  54.2  0  0  51.0 0.4  0  
  CD8  Clone #6-1  65.0  0.9  1.5 56.9  0.8  0  
 Fas−/− CD4  Bulk #7-1  46.9  0.8  0  45.9  0.3  
   Clone #7-1  67.7  2.0  1.6  69.8  1.1 1.3  
   Clone #7-2  56.9  0.5  0.8  54.9 0.3  1.8  
  CD8  Clone #8-1  75.2  2.9  0.7 70.8  0.8  
Donor StimulatorPhenotype Effector % Specific Lysis of Target Cells*
Allo LCL (Fas+/−) Allo LCL (Fas−/−)
None EGTACMA None EGTA CMA
M.Y.  Fas+/− CD4  Bulk #1-1  45.8  0.8  1.5  43.0  0  
   Clone #1-1  76.1  2.6  0.5  75.0  0.1 0.9  
   Clone #1-2  52.8  0.3  0.1  49.8 0.1  0  
  CD8  Clone #2-1  78.0  2.0  0.4 76.9  2.0  1.7  
 Fas−/− CD4 Bulk #3-1  34.0  0  0.3  38.9  0.7  1.0 
   Clone #3-1  69.2  0.1  0.5  65.8  0.8  
   Clone #3-2  60.0  1.0  0  58.2 0  0  
  CD8  Clone #4-1  78.9  2.1  1.0 76.3  0.8  0.3  
H.O.  Fas+/− CD4 Bulk #5-1  42.9  0.5  1.6  40.5  0.6  
   Clone #5-1  65.2  0.6  1.0  66.6  1.7  
   Clone #5-2  54.2  0  0  51.0 0.4  0  
  CD8  Clone #6-1  65.0  0.9  1.5 56.9  0.8  0  
 Fas−/− CD4  Bulk #7-1  46.9  0.8  0  45.9  0.3  
   Clone #7-1  67.7  2.0  1.6  69.8  1.1 1.3  
   Clone #7-2  56.9  0.5  0.8  54.9 0.3  1.8  
  CD8  Clone #8-1  75.2  2.9  0.7 70.8  0.8  
*

Cytotoxicity of CD4+ and CD8+ CTL bulk lines and clones generated by stimulation of PBMCs isolated from unrelated donors with HLA class I and class II-mismatched Fas+/− or Fas−/− LCL against Fas+/− and Fas−/− target cells in the presence or absence of EGTA or CMA, as detailed in “Materials and methods.” Effector/target ratios were 5:1.

Cytokine production by alloantigen-specific CD4+ CTL clones

Alloantigen-specific CD4+ CTL clones were cultured with or without Fas+/− and Fas−/−LCL, and the supernatants were analyzed for the production of IL-4, IL-10, and interferon (IFN)-γ. As shown in Table3, the majority of CD4+ CTL clones secreted all of these cytokines after stimulation with allogeneic LCL. Some of the CD4+ CTL clones secreted IL-10 and IFN-γ, but not IL-4. Therefore, the majority of alloantigen-specific human CD4+ CTLs generated in the present study can be classified as TH0 type CD4+ T-cell clones, with coexisting TH1 clones.

Table 3.

Cytokine production by alloantigen-specific CD4+ CTL clones

Donor Effector StimulatorCytokine production (pg/mL)3-150
IL-4 IL-10IFN-γ
M.Y.  CD4+ clone #1-1  Auto LCL  44  135  
  Fas+/− LCL  118  3,492  1,812 
 CD4+ clone #1-2  Auto LCL  0  103  274 
  Fas+/− LCL  123  3,684  1,952 
 CD4+ clone #3-1  Auto LCL  0  133  209 
  Fas−/− LCL  0  3,812  1,924 
 CD4+ clone 3-2  Auto LCL  0  84  183 
  Fas−/− LCL  156  3,060  2,224  
H.O. CD4+ clone #5-1  Auto LCL  0  172  85 
  Fas+/− LCL  118  3,260  2,048 
 CD4+ clone #5-2  Auto LCL  0  131  284 
  Fas+/− LCL  123  3,668  2,096 
 CD4+ clone #7-1  Auto LCL  0  181  302 
  Fas−/− LCL  0  3,700  2,068 
 CD4+ clone #7-2  Auto LCL  0  238  160 
  Fas−/− LCL  157  3,760  1,696 
Donor Effector StimulatorCytokine production (pg/mL)3-150
IL-4 IL-10IFN-γ
M.Y.  CD4+ clone #1-1  Auto LCL  44  135  
  Fas+/− LCL  118  3,492  1,812 
 CD4+ clone #1-2  Auto LCL  0  103  274 
  Fas+/− LCL  123  3,684  1,952 
 CD4+ clone #3-1  Auto LCL  0  133  209 
  Fas−/− LCL  0  3,812  1,924 
 CD4+ clone 3-2  Auto LCL  0  84  183 
  Fas−/− LCL  156  3,060  2,224  
H.O. CD4+ clone #5-1  Auto LCL  0  172  85 
  Fas+/− LCL  118  3,260  2,048 
 CD4+ clone #5-2  Auto LCL  0  131  284 
  Fas+/− LCL  123  3,668  2,096 
 CD4+ clone #7-1  Auto LCL  0  181  302 
  Fas−/− LCL  0  3,700  2,068 
 CD4+ clone #7-2  Auto LCL  0  238  160 
  Fas−/− LCL  157  3,760  1,696 
F3-150

The CD4+ clone cells were cultured with or without allogeneic LCL for 72 hours, and the concentration of each cytokine in the culture supernatant was determined by ELISA.

In contrast to the detailed data available on the cytolytic mechanisms of murine CTLs obtained previously with the use of various kinds of mutant and knockout mice, the mechanisms of cytotoxicity mediated by human CTLs are still obscure. Using a novel experimental system with cells from family members with the Fas gene mutation, which is considered to be the human counterpart of the lpr mouse mutation, we have clearly demonstrated that granule exocytosis, and not the Fas/Fas ligand system, is the main pathway of cytotoxicity mediated by alloantigen-specific human CD4+ as well as CD8+ CTLs.

Cytotoxicity mediated by alloantigen-specific human CD4+ as well as CD8+ CTLs are Ca2+-dependent, since addition of the Ca2+-chelating agent EGTA to the assay medium resulted in complete abrogation of cytotoxicity. Although Fas-dependent cytotoxicity has been reported to be Ca2+-independent,23 subsequent studies have revealed that even though the interaction between Fas ligand and Fas is Ca2+-independent, T-cell receptor–dependent up-regulation of Fas ligand on the cell surface requires extracellular Ca2+.24 Therefore, it could not be concluded that cytotoxicity mediated by human CD4+ CTLs is Fas-independent on the basis of the results obtained from the experiments using EGTA. However, we could conclude that cytotoxicity mediated by alloantigen-specific human CD4+ CTLs is Fas-independent, since they lysed allogeneic Fas−/− and Fas+/− target cells, which shared an HLA haplotype, to the same degree. In addition, the cytotoxicity mediated by the CD4+ CTLs was almost completely inhibited by treatment with a potent inhibitor of the perforin-based cytotoxic pathway, CMA. These data strongly suggest that the main pathway of alloantigen-specific human CD4+CTL-mediated cytotoxicity is granule exocytosis and that the cytolytic mechanism of human CD4+ CTLs generated in vitro is basically identical to that of CD8+ CTLs.

The present data seem to be somewhat different from the recent findings obtained with murine systems indicating that granule exocytosis is the main pathway for CD8+ CTL– and natural killer cell–mediated cytotoxicity, whereas most CD4+ CTLs exert their cytotoxicity through the Fas/Fas ligand system.10,11In murine models of acute GVHD and graft rejection using granzyme B-deficient mice, it has been reported that granzyme B plays an important role in cytotoxicity mediated by CD8+ CTLs, but not by CD4+ CTLs.25 The possibility that perforin-dependent cytotoxicity is restricted to some limited CD4+ populations is unlikely, since all alloantigen-specific CD4+ CTL bulk lines and clones examined showed Fas-independent cytotoxicity, and we have reported recently that herpes simplex virus–specific human CD4+ CTLs also exert antigen-specific and HLA class II–restricted cytotoxicity through Fas-independent mechanisms.16 In addition, we have recently found that cytotoxicity mediated by peptide-specific human CD4+ CTL clones is also Fas-independent (unpublished data).

To clarify the subtype of CD4+ CTL clones generated in the present study, we examined their cytokine production profile. It appeared that the vast majority of CD4+ CTL clones generated were classified as TH0-type clones, and some CD4+ CTL clones secreted TH1-type cytokines. Although the relationship between the cytokine production profile and cytolytic pathway of CD4+ CTLs is unknown, the culture conditions of our experimental system might have favored the generation of TH0 CTLs, which predominantly follow the granule exocytosis pathway. Therefore, further study is necessary to clarify the cytolytic pathway of human CD4+ CTLs, which infiltrate various organs and exert cytotoxicity in vivo.

Although the mechanisms of graft rejection and GVHD are complex, CTLs directed against alloantigens undoubtedly play crucial roles in these serious problems associated with organ transplantation. Recent studies have shown that in addition to CD8+ CTLs, CD4+CTLs are also important for induction of graft rejection and GVHD.18,26 27 Thus, the present data indicate that we need to focus on the CTL granule exocytosis mechanism as well as the Fas/Fas ligand system when considering the development of novel methods for protection against alloreactivity.

Supported by grants from the Ministry of Education, Science, Sports and Culture of Japan; the Mochida Foundation for Medical and Pharmaceutical Research; the Inamori Foundation; the Suzuken Memorial Foundation; and the Naito Foundation.

Reprints: Masaki Yasukawa, The First Department of Internal Medicine, Ehime University School of Medicine, Shigenobu, Ehime 791-0295, Japan; e-mail: yasukawa@m.ehime-u.ac.jp.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 U.S.C. section 1734.

1
Henkart
 
PA
Lymphocyte-mediated cytotoxicity: two pathways and multiple effector molecules.
Immunity.
1
1994
343
2
Kägi
 
D
Ledermann
 
B
Bürki
 
K
Zinkernagel
 
RM
Hengartner
 
H
Molecular mechanisms of lymphocyte-mediated cytotoxicity and their role in immunological protection and pathogenesis in vivo.
Annu Rev Immunol.
14
1996
207
3
Watanabe-Fukunaga
 
R
Brannan
 
CI
Copeland
 
NG
Jenkins
 
NA
Nagata
 
S
Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis.
Nature.
356
1992
314
4
Takahashi
 
T
Tanaka
 
M
Brannan
 
CI
et al
Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand.
Cell.
76
1994
969
5
Kägi
 
D
Vignaux
 
F
Ledermann
 
B
et al
Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity.
Science.
265
1994
528
6
Lowin
 
B
Hahne
 
M
Mattmann
 
C
Tschopp
 
J
Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways.
Nature.
370
1994
650
7
Walsh
 
CM
Matloubian
 
M
Liu
 
C-C
et al
Immune function in mice lacking the perforin gene.
Proc Natl Acad Sci U S A.
91
1994
10,854
8
Kojima
 
H
Shinohara
 
N
Hanaoka
 
S
et al
Two distinct pathways of specific killing revealed by perforin mutant cytotoxic T lymphocytes.
Immunity.
1
1994
357
9
Simon
 
MM
Hausmann
 
M
Tran
 
T
et al
In vitro- and ex vivo-derived cytolytic leukocytes from granzyme A × B double knockout mice are defective in granule-mediated apoptosis but not lysis of target cells.
J Exp Med.
186
1997
1781
10
Kägi
 
D
Ledermann
 
B
Bürki
 
K
et al
Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice.
Nature.
369
1994
31
11
Stalder
 
T
Hahn
 
S
Erb
 
P
Fas antigen is the major target molecule for CD4+ T cell-mediated cytotoxicity.
J Immunol.
152
1994
1127
12
Rieux-Laucat
 
FR
Deist
 
FL
Hivroz
 
C
et al
Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity.
Science.
268
1995
1347
13
Fisher
 
GH
Rosenberg
 
FJ
Straus
 
SE
et al
Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome.
Cell.
81
1995
935
14
Nagata
 
S
Human autoimmune lymphoproliferative syndrome, a defect in the apoptosis-inducing Fas receptor: a lesson from the mouse model.
J Hum Genet.
43
1998
2
15
Kasahara
 
Y
Wada
 
T
Niida
 
Y
et al
Novel Fas (CD95/APO-1) mutations in infants with a lymphoproliferative disorder.
Int Immunol.
10
1998
195
16
Yasukawa
 
M
Ohminami
 
H
Yakushijin
 
Y
et al
Fas-independent cytotoxicity mediated by human CD4+ CTL directed against herpes simplex virus-infected cells.
J Immunol.
162
1999
6100
17
Yasukawa
 
M
Inatsuki
 
A
Kobayashi
 
Y
Helper activity in antigen-specific antibody production mediated by CD4+ human cytotoxic T cell clones directed against herpes simplex virus.
J Immunol.
140
1988
3419
18
Nishimura
 
M
Uchida
 
S
Mitsunaga
 
S
et al
Characterization of T-cell clones derived from peripheral blood lymphocytes of a patient with transfusion-associated graft-versus-host disease: Fas-mediated killing by CD4+ and CD8+ cytotoxic T-cell clones and tumor necrosis factor beta production by CD4+ T-cell clones.
Blood.
89
1997
1440
19
Gagnon
 
SJ
Ennis
 
FA
Rothman
 
AL
Bystander target cell lysis and cytokine production by dengue virus-specific human CD4+ cytotoxic T-lymphocyte clones.
J Virol.
73
1999
3623
20
Yasukawa
 
M
Inatsuki
 
A
Horiuchi
 
T
Kobayashi
 
Y
Functional heterogeneity among herpes simplex virus-specific human CD4+ T cells.
J Immunol.
146
1991
1341
21
Kataoka
 
T
Shinohara
 
N
Takamiya
 
H
et al
Concanamycin A, a powerful tool for characterization and estimation of contribution of perforin- and Fas-based lytic pathways in cell-mediated cytotoxicity.
J Immunol.
156
1996
3678
22
Yasukawa
 
M
Ohminami
 
H
Kaneko
 
S
et al
CD4+ cytotoxic T-cell clones specific for bcr-abl b3a2 fusion peptide augment colony formation by chronic myelogenous leukemia cells in a b3a2-specific and HLA-DR-restricted manner.
Blood.
92
1998
3355
23
Rouvier
 
E
Luciani
 
MF
Golstein
 
P
Fas involvement in Ca2+-independent T cell-mediated cytotoxicity.
J Exp Med.
177
1993
195
24
Lowin
 
B
Mattman
 
C
Hahne
 
M
Tschopp
 
J
Comparison of Fas (Apo-1/CD95)- and perforin-mediated cytotoxicity in primary T lymphocytes.
Int Immunol.
8
1996
57
25
Graubert
 
TA
Russell
 
JH
Ley
 
TJ
The role of granzyme B in murine models of acute graft-versus-host disease and graft rejection.
Blood.
87
1996
1232
26
Friedman
 
T
Shimizu
 
A
Smith
 
RN
et al
Human CD4+ T cells mediate rejection of porcine xenografts.
J Immunol.
162
1999
5256
27
Faber
 
LM
van Luxemburg-Heijis
 
SAP
Veenhof
 
WFJ
Willemze
 
R
Falkenburg
 
JHF
Generation of CD4+ cytotoxic T-lymphocyte clones from a patient with severe graft-versus-host disease after allogeneic bone marrow transplantation: implication for graft-versus-leukemia reaction.
Blood.
86
1995
2821
Sign in via your Institution